The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Tandem Meetings 2023 | Tandem Meetings myeloma highlights: pano/GemBuMel with autoSCT, KarMMa-3 & more
Muzaffar Qazilbash, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares his highlights in multiple myeloma from this year’s Tandem Meetings. Prof. Qazilbash first comments on the results of a Phase II study of panobinostat, gemcitabine, busulfan and melphalan (GemBuMel) with autologous stem cell transplant (autoSCT) which showed a benefit in patients with high-risk or relapsed/refractory (R/R) multiple myeloma (NCT02506959). Prof. Qazilbash then discusses the findings of the Phase III KarMMa-3 study (NCT03651128) which demonstrated a benefit in progression-free survival (PFS) for patients treated with idecabtagene vicleucel (ide-cel) versus standard regimens, and highlights the benefit of this agent in patients with renal impairment. Nevertheless, Prof. Qazilbash notes that PFS with ide-cel is still suboptimal and toxicity rates remain high. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
